Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study

Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study

ABSTRACT Background and Aims People living with human immunodeficiency virus (HIV, PLWH) are aging, and there are growing concerns regarding combined antiretroviral therapy (cART)‐associated negative metabolic consequences. We aimed to investigate the metabolic outcomes of PLWH by replacing rilpivir...

Full description

Saved in:
Bibliographic Details
Main Authors: Ping‐Feng Wu, Hsi‐Hsun Lin, Hsin‐Pai Chen, Po‐Chieh Huang, Meng‐Yu Ke
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:Health Science Reports
Subjects:
HIV
lipids
metabolic syndrome
tenofovir alafenamide
tenofovir disoproxil fumarate
Online Access:https://doi.org/10.1002/hsr2.70275
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items